NEU-723 has been shown in preclinical studies to have strong disease-modifying potential with a higher therapeutic index than other candidates in development
Neuron23 Announces First-in-Human Dose in... - Cure Parkinson's
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinsons Disease
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Not what you're looking for?
You may also like...
BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107,ERK inhibitor that selectively inhibits neuroinflammation
BioVie announces treatment of 1st patient in Phase 2 clinical trial of NE3107 (an ERK inhibitor...
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s...
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
This trial is already open in the United States, and I believe some on this forum are...
ANNOVIS BIO ANNOUNCES POSITIVE FDA NOTICE FOR BUNTANETAP PHASE 3 CLINICAL TRIAL IN PARKINSON'S DISEASE
https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=e4e0b40
ANNOVIS BIO ANNOUNCES POSITIVE FDA FEEDBACK FOR BUNTANETAP PHASE 3 CLINICAL DEVELOPMENT IN PARKINSON'S DISEASE (ANVS401)
https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?releaseID=111474&d=20